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The objectives of this study were to compare the molecular and biological characteristics of recent porcine
reproductive and respiratory syndrome virus (PRRSV) field isolates to those of a modified live virus (MLV)
PRRS vaccine and its parent strain. One hundred seventeen, 4-week-old pigs were randomly assigned to six
groups. Group 1 (n  20) served as sham-inoculated negative controls, group 2 (n  19) was inoculated with
Ingelvac PRRS MLV vaccine, group 3 (n  20) was inoculated with the parent strain of the vaccine (ATCC
VR2332), group 4 (n 19) was inoculated with vaccine-like PRRSV field isolate 98-38803, group 5 (n 19) was
inoculated with PRRSV field isolate 98-37120, and group 6 (n  20) was inoculated with known high-virulence
PRRSV isolate ATCC VR2385. The levels of severity of gross lung lesions (0 to 100%) among the groups were
significantly different at both 10 (P < 0.0001) and 28 days postinoculation (p.i.) (P  0.002). At 10 days p.i.,
VR2332 (26.5%  4.64%) and VR2385 (36.4%  6.51%) induced gross lesions of significantly greater severity
than 98-38803 (0.0%  0.0%), 98-37120 (0.8%  0.42%), Ingelvac PRRS MLV (0.9%  0.46%), and negative
controls (2.3%  1.26%). At 28 days p.i., 98-37120 (17.2%  6.51%) induced gross lesions of significantly
greater severity than any of the other viruses. Analyses of the microscopic-interstitial-pneumonia-lesion scores
(0 to 6) revealed that VR2332 (2.9  0.23) and VR2385 (3.1  0.35) induced significantly more severe lesions
at 10 days p.i. At 28 days p.i., VR2385 (2.5  0.27), VR2332 (2.3  0.21), 98-38803 (2.6  0.29), and 98-37120
(3.0  0.41) induced significantly more severe lesions than Ingelvac PRRS MLV (0.7  0.17) and controls (0.7
 0.15). The molecular analyses and biological characterizations suggest that the vaccine-like isolate 98-38803
(99.5% amino acid homology based on the ORF5 gene) induces microscopic pneumonia lesions similar in type
to, but different in severity and time of onset from, those observed with virulent strains VR2385 and the parent
strain of the vaccine. Our data strongly suggest that isolate 98-38803 is a derivative of Ingelvac PRRS MLV and
that the isolate is pneumovirulent.
Porcine reproductive and respiratory syndrome (PRRS) was
first reported in the United States in 1987 (19). The causal
agent of PRRS was first isolated in The Netherlands in 1991
(37) and was determined to be a small, enveloped, positive-
sense, single-strand RNA virus referred to as PRRS virus
(PRRSV). PRRSV is classified in the order Nidovirales, family
Arteriviridae, genus Arterivirus (6).
PRRSV is endemic in most swine-producing countries, and
today it is associated with major economic losses. Clinical signs
of PRRS in growing pigs include fever, anorexia, and respira-
tory disease characterized by dyspnea and tachypnea. Repro-
ductive failure associated with PRRSV is characterized by
mid- to late-term abortions, increased numbers of mummified
fetuses, decreased numbers of pigs born alive, increased num-
bers of weak-born pigs, and generally poor reproductive per-
formance (10, 11).
Modified live commercial PRRSV (MLV) vaccines such as
Ingelvac PRRS MLV (Boehringer Ingelheim Vetmedica, Inc.)
for prevention and control have been available since June
1994. Shedding and spread of vaccine virus between vaccinated
pigs and nonvaccinated contact controls have been reported to
occur (36). Spread of vaccine strains of PRRSV in semen from
boars in vaccinated boar studs to naive breeding herds has also
been demonstrated to occur and to induce disease (34). A U.S.
study demonstrated that boars vaccinated with PRRS MLV
shed vaccine virus in semen up to 2 weeks after vaccination.
But, after challenge with a wild-type virus, the shedding of the
wild-type virus was shortened or eliminated. The semen quality
in vaccinated boars after challenge was significantly reduced
(9).
In 1996, veterinary practitioners and diagnosticians began to
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report disease outbreaks described as swine abortion and mor-
tality syndrome, atypical PRRS, or acute PRRS (5, 17). Many
of the affected herds had been vaccinated multiple times with
modified live PRRSV vaccine, yet they experienced clinical
outbreaks characterized by mid- or late-term abortions, with
an incidence of 10 to 50% of the herd affected in a 1- to 5-week
period. In the majority of the acute PRRS cases, diagnosticians
observed microscopic lesions typical of PRRSV (interstitial
pneumonia, encephalitis, and myocarditis). In some field cases
of severe reproductive failure in breeding herds and respira-
tory disease in growing pigs, the only infectious agent detected
was a PRRSV isolate that, based on genomic sequencing and
restriction fragment length polymorphism patterns, was highly
homologous to the vaccine (Ingelvac PRRS MLV) used in the
herd (38). This raised concern from practitioners and produc-
ers over vaccine efficacy and safety.
Concerns over PRRS MLV vaccine safety arose in Denmark
following the use of PRRS MLV vaccine in 1996 as part of a
national PRRSV control program. The program included the
vaccination of PRRSV-seropositive herds and of boars in ar-
tificial-insemination centers with a PRRS MLV vaccine. In
1997 there were multiple outbreaks of “severe PRRS” in Dan-
ish swine herds, both vaccinated and unvaccinated. The only
PRRSV isolated from these affected herds was a virus with 99.2
to 99.5% sequence identity to the Ingelvac PRRS MLV vac-
cine (4, 22), which was the vaccine used in the control program.
PRRSV isolates from these cases showed 99.0 to 99.3% nucle-
otide sequence identities with VR2332 (22). The North Amer-
ican type of PRRSV had not previously been recognized in
Denmark or elsewhere in Europe. A comparison of the se-
quences of the open reading frame 1 (ORF1) regions of In-
gelvac PRRS MLV vaccine, the parental strain of the vaccine
(VR2332), vaccine-derived field isolates collected from vacci-
nated herds 2 to 5 months after vaccination, and two isolates
from nonvaccinated herds isolated 6 months after the begin-
ning of the federal vaccination program was carried out. Five
mutations that occurred in all three examined vaccine-derived
isolates indicated a strong parallel pressure on these positions
in the vaccine virus (33). Taken together, the data suggested
that the MLV vaccine had spread from the vaccinated herds to
other nonvaccinated PRRSV-naive herds.
In 1999, the ORF5 and ORF7 genes of 20 Danish field
isolates were sequenced to determine relatedness to the Ingel-
vac PRRS MLV vaccine. It was found that MLV vaccines such
as the Ingelvac PRRS MLV have a tendency to spread in a
swine population and to revert to a state of greater virulence
(35). In all 20 isolates, a total of 52 nucleotide mutations in the
ORF5 gene sequence compared to the ORF5 sequence of the
vaccine virus were found. Only seven of these mutations were
synonymous. At amino acid positions 13 and 151, the se-
quences of many of the Danish isolates had reverted to that of
the wild-type parental strain (VR2332).
It has been documented that PRRSV strains differ in viru-
lence (14–16, 30) and vary genetically (23–27). Concerns that
vaccine strains or derivatives of the vaccine strains may induce
disease continue to be discussed (20, 28, 36). The objective of
this research was to compare the pathogenicity of two U.S.
PRRSV isolates with a high sequence homology with Ingelvac
vaccine virus from cases of severe PRRS outbreaks to that of
a known high-virulence PRRSV isolate (ATCC VR2385), the
Ingelvac PRRS MLV vaccine, and the parent strain of the
vaccine (ATCC VR2332) in a well-established PRRSV model
(14, 15).
MATERIALS AND METHODS
Animal source. One hundred seventeen, specific-pathogen-free pigs from a
PRRSV-free herd were purchased, weaned, and transported to the Iowa State
University research facility at 12 to 14 days of age. To confirm the negative
PRRSV status of the pigs, a commercial enzyme-linked immunosorbent assay
(ELISA; PRRSV antibody test kit; IDEXX Laboratories, Inc., Westbrook,
Mass.) was performed on serum samples collected on arrival and again prior to
inoculation at 4 weeks of age.
Virus inocula. Five different PRRSV isolates were used: ATCC VR2385 (28),
ATCC VR2332 (31), which is the parent strain of Ingelvac PRRS MLV vaccine,
Ingelvac PRRS MLV vaccine (lot JA-621C-416) in a 2-ml dose in an extralabel
fashion (intranasal inoculation), isolate 98-37120 (5, 20), and isolate 98-38803.
Isolate 98-37120 was isolated from a farm in Iowa containing nonvaccinated
swine that experienced characteristic symptoms of acute PRRS (5). Isolate 98-
38803 was from a 300-sow herd in Iowa that experienced 80 abortions over a
5-week period and high preweaning (50%) and growing-pig mortality (15%)
associated with PRRSV-induced pneumonia and secondary infections. Gilts in
this herd were vaccinated with Ingelvac PRRS MLV approximately 60 days prior
to introduction to the herd.
The virus inocula were prepared as previously described (40). For each virus
inoculum, a plaque-purified virus stock was propagated in confluent monolayers
of MARC-145 cells (21). All virus inocula were adjusted to a final titer of 105.5
50% tissue culture infectious doses/2 ml. A 2-ml inoculation was given intrana-
sally by slowly dripping the inoculum into the nostrils. Controls were inoculated
with uninfected cell culture lysates.
Experiment design. The pigs were randomly assigned to one of six groups of
19 or 20 animals each. Each group was housed in a separate power-ventilated
room. At 4 weeks of age all groups were inoculated intranasally with 2 ml of one
of the different PRRSV isolates (field isolates 98-38803 and 98-37120, VR2332,
and VR2385) or the vaccine (Ingelvac PRRS MLV vaccine) or were sham
inoculated with cell culture media from uninfected cells. Clinical observations
including respiratory disease scores ranging from 0 to 6 (0, normal; 6, severe) and
rectal temperature were recorded every other day from 0 to 28 days postinocu-
lation (p.i.) (14, 15). Blood was collected prior to inoculation and at 6, 14, 21, and
28 days p.i. for virus assays and serology. Necropsy was performed on 10 ran-
domly selected pigs from each group at 10 days p.i. and on the remainder at 28
days p.i. Bronchoalveolar lavage (BAL) fluid was collected as described previ-
ously (29) at necropsy at 10 and 28 days p.i.
Serology. A commercial PRRSV ELISA (IDEXX Laboratories, Inc.) kit was
used to detect and compare the anti-PRRSV antibody responses of the pigs prior
to and after inoculation. According to the manufacturer, samples with sample-
to-positive (S/P) ratios 0.4 were considered positive for antibodies against
PRRSV.
Gross pathology and histopathology. Complete necropsies were performed on
all pigs, and all organ systems were examined. All lungs were examined in blind
fashion and given a subjective score for severity of gross lung lesions using an
established scoring system that estimates the percentage of lung affected by
pneumonia (14, 15). Samples of lung (two sections from the cranial lobe and one
from each of middle, accessory, and caudal lung lobes), heart, kidney, ileum,
spleen, tonsil, and tracheobronchial and mediastinal lymph nodes were collected
and fixed in 10% neutral buffered formalin and routinely processed for his-
topathological examination. The microscopic sections were examined in blind
fashion and assigned a score for severity of interstitial pneumonia (0 to 6) as
previously described (14, 15).
Immunohistochemistry. Immunohistochemistry of paraffin-embedded blocks
of lung and lymph nodes for detection of PRRSV antigen was performed as
previously described (13) by using a cocktail of two different mouse monoclonal
antibodies, SDOW-17 in a dilution of 1/5,000 and SR-30 in a dilution of 1/1,500.
RT-PCR. Reverse transcription-PCR (RT-PCR) and PRRSV isolation from
BAL fluid were attempted (39). In the pigs where the BAL fluid tested negative
for PRRSV, serum was tested by PCR. If serum also tested negative for PRRSV,
tonsils from those pigs were tested by PCR. BAL fluid was collected aseptically
with 50 ml of lavage fluid consisting of Earle’s balanced salt solution (Sigma
Chemical Co., St. Louis, Mo.). The BAL fluid was kept at 70°C until used for
RT-PCR. Prior to RNA extraction, the BAL fluid was frozen and thawed three
times. After centrifugation at 2,000  g for 10 min at 4°C, 140 l of the
supernatant was used for RNA extraction with the QIAamp viral RNA minikit
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(Qiagen Inc., Valencia, Calif.) according to the instructions of the manufacturer.
RT-PCR was carried out by using the One Step RT-PCR kit (Qiagen Inc.). Eight
microliters of the RNA template was added to 42 l of the RT-PCR master
mixture. PCR was performed with a set of primers corresponding to conserved
regions in the ORF7 as previously described (7, 8).
Viral sequence analysis. Two PCR products amplified from each group, one at
10 days p.i. and one at 28 days p.i., were sequenced in the ORF5 gene (GenBank
accession no. PRU87392; primer locations: P5F, positions 13696 to 13714; P5R,
positions 14459 to 14437; PCR product length: 764 bp) to confirm that the isolate
used in the respective inoculum was the same as the one replicating in the
respective pigs. The PCR amplification of the target gene and preparation for
sequencing were performed as previously described (7).
Sequencing was performed at the Iowa State University Nucleic Acid Facility
(Ames, Iowa). Sequences were aligned and analyzed with the DNAstar (DNA
STAR Inc., Madison, Wis.) computer program.
Statistical analysis. The data from repeated measurements of rectal temper-
ature were analyzed by using multivariate analysis of variance, which accounts for
the within-subject correlation. The asymmetries of the histograms in terms of
percentage of gross lung lesions and the sample size of 10 per group suggested
that it was appropriate and conservative to use the nonparametric Kruskal-Wallis
analysis of variance (ANOVA) to test for a difference in group distributions. If
the ANOVA was significant (P  0.05), post hoc tests (pair-wise Wilcoxon tests)
were then used to determine the relationships among the groups. Gross lesions
and microscopic-interstitial-pneumonia scores were ordinal variables, so
Kruskal-Wallis ANOVA was used to test for a difference in the group distribu-
tions.
RESULTS
Clinical signs. The negative-control group and the Ingelvac
PRRS MLV-inoculated group showed no clinical signs of ill-
ness at any time during the experiment. Rectal temperatures
and respiratory disease scores from these two groups were
within normal range. Pigs in the VR2332 and VR2385 groups
exhibited dyspnea, tachypnea, and lethargy beginning at 5 to 7
days p.i.; symptoms became moderate to severe by 10 days p.i.
and resolved by 14 to 21 days p.i. In contrast, pigs inoculated
with field isolates 98-38803 and 98-37120 had a different tem-
poral pattern of disease manifestation. Pigs in these groups did
not display clinical signs until 21 days p.i. Respiratory disease
(dyspnea and tachypnea), fever, and lethargy in these groups
were mild to moderate from 21 days through the termination
of the study at 28 days p.i.
Statistical evaluation of the clinical-sign scores suggested no
significant differences between the groups. The scores for the
control group and the Ingelvac PRRS MLV group were gen-
erally lower than the scores for the other groups. The variation
among groups decreased as days p.i. increased. The statistical
analysis of the data from repeated measurements of rectal
temperature resulted in a statistically significant (P  0.05)
group by time interaction. The relationship among the group
averages changed with days p.i., and no group average was
uniformly different from the others over time. Inspection of the
plot of temperature means versus days p.i. showed no clear
patterns, such as trends, except a reduction in variation at 14,
16, and 18 days p.i.
Gross lesions. Gross-lung-lesion scores are summarized in
Table 1. When observed, the PRRSV-induced lesions were
similar in type but different in severity among the groups.
PRRSV-induced gross lesions were characterized by failure of
the lung to collapse and mottled tan, moderately well demar-
cated areas of pneumonia. The lesions were observed most
often in the cranioventral portions but were also found multi-
focally throughout the lung. At 10 days p.i., gross lung lesions
in the VR2385 and VR2332 groups were significantly (P 
0.0001) more severe than those in the other groups. At 28 days
p.i., there were significantly (P  0.002) more severe gross
lesions in the 98-37120 group than in all other groups.
Microscopic lesions. Microscopic lung lesions in the
PRRSV-inoculated groups were similar in type but varied in
severity and timing of onset and resolution. The lesions were
characterized by type 2 pneumocytic hypertrophy and hyper-
plasia, septal infiltration with mononuclear cells, and increased
amounts of alveolar exudate and necrotic debris. Lesions in the
VR2332 and VR2385 groups were moderate to severe at 10
days p.i. and mild to moderate by 28 days p.i. Lung lesions in
groups 98-37120 and 98-38803 were minimal or absent at 10
days p.i. but were mild to moderate at 28 days p.i. (Fig. 1).
Lesions in controls and Ingelvac PRRS MLV groups were
essentially unremarkable at both 10 and 28 days p.i. Micro-
scopic lung lesions in the VR2385 and VR2332 groups were
significantly (P  0.0001) more severe than those in all other
groups at 10 days p.i. At 28 days p.i., the microscopic lesions in
the VR2385, VR2332, 98-37120 and 98-38803 groups were
significantly (P  0.0001) more severe than those in controls
and the Ingelvac PRRS MLV group (Table 1).
None of the pigs in the control or Ingelvac PRRS MLV
group had microscopic evidence of myocarditis, whereas 7 of
19, 8 of 19, 8 of 20, and 8 of 20 pigs in the 98-38803, 98-37120,
VR2385, and VR2332 groups, respectively, had mild lympho-
plasmacytic myocarditis.
Antibody response. All pigs were negative (S/P  0.4) for
PRRSV serum antibodies at the time of arrival (10 to 12 days
of age) and at the time of inoculation (4 weeks of age). Neg-
ative-control pigs remained negative for PRRSV antibodies
throughout the study.
Pigs in the VR2332 and VR2385 groups all seroconverted to
anti-PRRSV between 6 and 14 days p.i. and showed similar
antibody responses (Fig. 2). The serological profile for the
98-38803 group was similar to those for the VR2332 and
VR2385 groups. None of the pigs seroconverted before 14 days
p.i., and the highest peak in S/P ratio was seen at 21 days p.i.
In the 98-37120 group, the antibody response to PRRSV was
first detected at 14 days p.i., with four of nine pigs positive; by
ELISA, seven of nine pigs were positive at 21 days p.i. and
eight of nine pigs were positive at 28 days p.i. The serological
TABLE 1. Comparison of PRRSV-induced gross and microscopic
lung lesions at 10 and 28 days p.i.c
Group
Gross-lung-lesion
score (%)a at:
Microscopic-lesion
scoreb at:
10 days p.i. 28 days 10 days p.i. 28 days p.i.
Negative control 2.3 (1.26)A 4.3 (1.03)A 0.4 (0.22)A 0.7 (0.15)A
Ingelvac PRRSV 0.9 (0.46)A 4.2 (1.06)A 0.0 (0.0)A 0.7 (0.17)A
VR2332 26.5 (4.64)B 9.6 (1.9)A 2.9 (0.23)B 2.3 (0.21)B
98-38803 0.0 (0.0)A 7.1 (1.9)A 0.3 (0.15)A 2.6 (0.29)B
98-37120 0.8 (0.42)A 17.2 (6.51)B 0.6 (0.27)A 3.0 (0.41)B
VR2385 36.4 (6.51)B 3.8 (0.7)A 3.1 (0.35)B 2.5 (0.27)B
a Mean (standard error of the mean) gross-lung-lesion score estimates the
percentage of the lung affected by pneumonia.
b Interstitial-pneumonia score. Range, 0 to 6. 0, no microscopic lesions; 1, mild
multifocal lesions; 2, mild diffuse lesions; 3, moderate multifocal lesions; 4,
moderate diffuse lesions; 5, severe multifocal lesions; 6, severe diffuse interstitial-
pneumonia lesions.
c Different superscripts (A and B) within each column indicate significantly
different values as determined by Kruskal-Wallis ANOVA.
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profile of group 2 (Ingelvac PRRS MLV vaccine) was some-
what different from those of the other groups: 0 of 20 pigs at 6
days p.i., 2 of 9 pigs at 14 days p.i., 4 of 9 pigs at 21 days p.i.,
and 5 of 9 pigs at 28 days p.i. were positive.
RT-PCR. The sham-inoculated negative-control group was
free of PRRSV throughout the study. All pigs in the VR2332
and VR2385 groups were positive for PRRSV nucleic acids by
RT-PCR of BAL fluid at 10 and 28 days p.i. In the 98-38803
FIG. 1. Comparison of PRRSV-induced microscopic lung lesions at 28 days p.i. Shown are sections of lungs from pigs in Ingelvac PRRS MLV
(A), VR2332 (B), 98-38803 (C), 98-37120 (D), and VR2385 (E) groups. Lesion severity ranges from no lesions (A) to moderate (B, C, and E) to
severe (D) interstitial pneumonia.
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group, 9 of 10 pigs were positive by PCR at 10 days p.i. and
BAL fluid for 9 of 9 pigs was positive at 28 days p.i. In group
98-37120 BAL fluid for 7 of 10 pigs was positive by PCR at 10
days p.i. Among the three pigs in the 98-37120 group whose
BAL fluid was PCR negative, one of three had positive serum
and the remaining two had negative serum and tonsil. At 28
days p.i., BAL fluid from eight of nine of the 98-37120 pigs was
positive by PCR. The negative pig also had negative serum and
tonsil. In contrast, in the Ingelvac PRRS MLV group, 1 of 10
pigs was positive by RT-PCR at 10 days p.i. and 2 of 9 pigs had
BAL fluid positive by RT-PCR at 28 days p.i. RT-PCR of
serum samples of Ingelvac PRRS MLV-inoculated pigs dem-
onstrated that four of nine pigs were positive at 10 days p.i. and
three of seven pigs were positive at 28 days p.i. In the Ingelvac
PRRS MLV-inoculated pigs whose BAL fluid and serum were
negative by RT-PCR, tonsil was also tested and one additional
positive animal was identified. Overall 6 of 10 Ingelvac PRRS
MLV-inoculated pigs were positive at 10 days p.i. and 5 of 9
were positive at 28 days p.i.
Nucleotide sequencing and sequence analysis. All isolates
described in this paper can be found in the GenBank database
under accession numbers AF066183 (Ingelvac PRRS MLV
vaccine), PRU87392 (VR2332), AF535152 (98-38803),
AF339499 (98-37120), and U03040 (VR2385). Sequence anal-
ysis of the ORF5 gene identified three phylogenetically distinct
clusters: Ingelvac PRRS MLV, VR2332, and 98-38803 are
closely related, while groups 98-37120 and VR2385 are located
in other branches (Fig. 3). Based on the sequence of ORF5
gene, 98-38803 is most closely related (99.5% amino acid se-
quence identity) to the Ingelvac PRRS MLV vaccine strain
(Table 2). 98-37120 and Ingelvac PRRS MLV have 96% amino
acid sequence identity in the products of their ORF5 genes. Of
the PRRSV isolates used in this study, VR2385 appears to be
the most distinct.
Amino acid sequence identity between virus isolates recov-
ered from pigs and the respective original inocula in groups
VR2332, VR2385, 98-37120, and 98-38803 was 100%. The
virus isolate recovered from pigs in the Ingelvac PRRS MLV
group had 99.5 to 100% sequence identity with the original
virus inoculum.
The sequence of a virus isolate from one pig in the Ingelvac
PRRS MLV group (pig 81, necropsied at 10 days p.i.) was
found to be 99.5% identical to the sequence of the virus inoc-
ulum (Ingelvac PRRS MLV) and 99.5% identical to the se-
quence of VR2332 (the parent strain of the vaccine). There are
only two amino acid differences in the products of the ORF5
genes of Ingelvac PRRS MLV and VR2332, one at position 13
and the other at position 151. VR2332 has an arginine at both
positions, whereas Ingelvac PRRS MLV has a glutamine at
position 13 and a glycine at position 151. The isolate from pig
81 had the change from glycine to arginine at position 151, and
therefore its ORF5 gene was as closely related to that of
Ingelvac PRRS MLV as to that of VR2332.
Nucleotide sequence accession number. The nucleotide se-
quence of the ORF5 gene of PRRSV isolate 98-38803 has been
submitted to GenBank (accession no. AF535152).
FIG. 2. Comparison of the PRRSV ELISA means (S/P ratios)
among the PRRSV-inoculated groups. DPI, days p.i.
FIG. 3. Dendrogram of the ORF5 nucleotide sequences (positions 13696 to 14459 of the PRRSV gene; GenBank accession no. PRU87392)
of PRRSV isolates recovered from pigs at 10 (pigs 9, 41, 61, and 81) and 28 days p.i. (pigs 11, 51, 71, and 99). 98-38803, pigs 9 and 11; 98-37120,
pigs 22 and 31; VR2385, pigs 41 and 51; VR2332, pigs 61 and 71; Ingelvac PRRS MLV, pigs 81 and 99. The phylogenetic relationships were
estimated by using the ClustalV method.
TABLE 2. Pair-wise comparison of the amino acid sequences of the
ORF5 gene products among PRRSV inocula used in the study
Virus
inoculum
% Identity to product of sequence with GenBank accession no.:
U03040 AF535152 AF339499 AF066183 PRU87392
VR2385 100 91.1 91.0 90.6 90.6
98-38803 91.1 100 95.5 99.5 98.5
98-37120 91.0 95.5 100 96.0 96.0
Ingelvac 90.6 99.5 96.0 100 99.0
VR2332 90.6 98.5 96.0 99.0 100
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DISCUSSION
PRRSV 98-38803 was isolated from a sow herd with
PRRSV-induced abortions and PRRSV-related respiratory
disease in growing pigs. The gilts prior to introduction into the
herd were vaccinated with Ingelvac PRRSV MLV vaccine.
PRRSV was isolated from the tissues of affected sows via
passage in cell culture. The product of the ORF5 gene of the
98-38803 isolate from this herd has 99.5% amino acid sequence
identity to that of the Ingelvac PRRSV MLV vaccine. Al-
though the two viruses are genetically very similar, the results
of this study, using a respiratory model, indicate that there are
significant biological differences between 98-38803 and the In-
gelvac MLV vaccine. The 98-38803 isolate replicated better in
pigs and induced higher ELISA S/P ratios than Ingelvac PRRS
MLV. Isolate 98-38803 also induced significantly more severe
microscopic lung lesions (P  0.0001) at 28 days p.i. than
Ingelvac PRRS MLV or controls. In addition, none of the pigs
in the Ingelvac PRRS MLV group had myocarditis, whereas 7
of 19 pigs in the 98-38803 group had myocarditis. Isolate 98-
38803 is considerably less virulent than highly virulent PRRSV
strain VR2385 and produces a later onset of respiratory symp-
toms. Pigs infected with 98-38803 showed evidence of mild
clinical disease nearly 2 weeks after the group inoculated with
the highly virulent strain did. When VR2385 pigs were recov-
ering from the disease, pigs in the 98-38803 group began to
show signs of respiratory disease and fevers. This was further
supported by observation of mild-to-moderate interstitial
pneumonia lesions in the 98-38803 group at 28 days p.i.
The second field isolate used in this study, 98-37120, biolog-
ically behaved most similar to 98-38803 in onset, duration, and
severity of disease and appears to be moderate in virulence.
The virus was one of eight acute PRRSV isolates genetically
analyzed by Key et al. (20). Among the ORF5 genes of these
acute PRRSV isolates, that of 98-37120 had the highest se-
quence identity to those of Ingelvac PRRS MLV and VR2332.
Our sequence analysis showed that the ORF5 gene product of
the 98-37120 isolate has 96% amino acid sequence identity to
those of Ingelvac PRRS MLV and VR2332 and 95.5% amino
acid sequence identity to that of 98-38803. Between the 200-
amino-acid ORF5 gene products of Ingelvac PRRS MLV and
98-37120 there are six amino acid differences. The positions
are 29 (valine), 30 (aspartic acid), 34 (asparagine), 35 (aspar-
agine), 58 (glutamic acid), and 151 (arginine). 98-37120 and
VR2385 have three of these changes in common, positions 29,
34, and 151. Isolates 98-37120, VR2332, and Ingelvac PRRS
MLV all have an isoleucine at position 189. Consequently,
sequence analysis did not suggest that isolate 98-37120 is a
direct derivative of the Ingelvac PRRS MLV.
There is still the question of whether field isolate 98-38803 is
a direct derivative of the Ingelvac PRRS MLV vaccine, a pos-
sible recombinant of the vaccine virus and a wild-type virus, or
a truly wild-type virus that is highly homologous to the original
parent vaccine strain, VR2332, which may be still circulating in
the field. Although answering such a question may require
whole-genome sequencing, sequence analysis of ORF5, a
highly variable gene of PRRSV, provides some clues. ORF5 is
a region containing 603 bases and encoding the major envelope
glycoprotein (25 kDa). Although ORF5 is only a small part of
the entire PRRSV genome, which contains 15,000 bases, it is
known to have the most variable sequence among isolates (18).
Amino acid homology in the product of ORF5 revealed a very
close relationship between 98-38803 and the Ingelvac PRRS
MLV vaccine, as isolate 98-38803 showed 99.5% identity, while
the isolate has 98.5% homology with the vaccine parent strain,
VR2332. Our conclusion may be supported by a recent study
by Chang et al. (7) suggesting that sequence divergence of
ORF5 between the parental strain and its derivatives should be
less than 1% after 1 year of in vivo replication in pigs. The only
difference in the product of ORF5 between Ingelvac PRRS
MLV vaccine and 98-38803 was found at position 189: the
98-38803 isolate had a valine, whereas the Ingelvac PRRS
MLV had an isoleucine. Furthermore, like the Ingelvac PRRS
MLV, isolate 98-38803 had a glycine at position 151. Wesley et
al. (38) described the glycine at residue 151 as an amino acid
marker that identifies the vaccine. Unlike the Ingelvac PRRSV
MLV vaccine, its parental strain, VR2332, has arginine at
position 151, which appears to be more stable and common
among wild-type PRRSVs (1, 2, 20). However, reversion from
glycine to arginine during in vivo replication of the vaccine
virus and cell-culture-adapted virus has been demonstrated (7,
38). In the context of the previous vaccination history in the
index herd, partial sequence analysis suggests that PRRSV
98-38803 is likely a direct derivative of the vaccine.
Provided that isolate 98-38803 is a descendant of Ingelvac
PRRS MLV, the question that still remains to be answered is
why 98-38803 is more virulent than the vaccine. Reversion of
the MLV vaccine strain to a virulent strain has also been
demonstrated by Storgaard et al. (35) using European field
isolates and by Allende et al. (2) using U.S. field isolates.
Although no genetic markers for the virulence of PRRSV have
been identified yet, it is interesting that isolate 98-38803 has
valine at position 189 like the known highly virulent PRRSV
VR2385 whereas Ingelvac PRRS MLV, VR2332, and isolate
98-37120 have isoleucine. Furthermore, this was the only
amino acid substituted among amino acids constituting the C
terminal region of the product of ORF5 (amino acids 164 to
200). The exact biological function of this region is unknown.
However, in many cases the C terminus of the envelope pro-
tein might play a role in signal transduction related to virus
replication. Whether such a substitution is of biological signif-
icance in the process of reversion to virulence remains to be
further studied.
While genetic markers for virulence remains to be found,
reversion of the vaccine virus to a virulent strain could be
attributed to recombination event between the vaccine strain
and field isolate. Experiments with distinct PRRSV isolates
growing in the same cell culture have shown that the ability of
the virus to build recombination is relatively high (32, 41, 42).
One group estimated that the frequency of such recombination
is from 2 to 10% in a 1,182-base fragment analyzed (41).
Although no recombinant PRRSV was obtained from pigs
inoculated with two different PRRSV field isolates or two
different PRRSV MLV vaccines (32, 41), the possibility of
recombination between vaccine and field strains due to vacci-
nation of PRRSV-infected herds must always be kept in mind.
In summary, our data strongly suggest that isolate 98-38803
is a derivative of Ingelvac PRRS MLV and that the isolate is
pneumovirulent. The obtained sequencing data indicate that,
based on the ORF5 gene, 98-38803 isolate is more closely
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related to Ingelvac PRRS MLV than to VR2332 and that
isolate 98-38803 is a descendant of the MLV. Whole-genome
sequencing for a better assessment of this remains to be con-
ducted. Inoculation of pregnant sows with the 98-38803 isolate
would provide further insight into the reproductive virulence
of the isolate. Consequently, when producers and veterinarians
choose to use MLV vaccines, they should consider the poten-
tial risk of reversion to virulence. However, MLV vaccines are
also an effective way of inducing immunity and protecting
herds from losses associated with infections by highly virulent
strains of PRRSV (3, 12). Producers and practitioners must
continually weigh the risks of vaccination versus no vaccina-
tion. Utilization of a protocol that focuses on population im-
mune management with vaccination or planned exposure may
minimize this risk.
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